FDA-approved atrasentan cuts proteinuria in IgA nephropathy, with ALIGN trial results, safety insights, and dosing cautions.
Chloe Hurme, BS, PharmD Candidate 2026
Advertisement
Articles by Chloe Hurme, BS, PharmD Candidate 2026
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Drug Topics
1
Repurposed Drugs Show Modest, Short-Term Benefit for Long COVID Fatigue
2
Emerging Data Show Potential Risk of Autoimmune Diseases With GLP-1 Use
3
FDA Approves First Oral PCSK9 Inhibitor to Lower LDL Cholesterol
4
Drug Shortages Are Down, But That's Not the Win It Sounds Like
5